BRIT: Platform for detecting dysbiosis of the intestinal microbiome through genetic sequencing

• Grant number: 23/12310-6
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: March 01, 2024
• End date: November 30, 2024
• Field of knowledge: Biological Sciences - Genetics - Molecular Genetics and Genetics of Microorganisms
• Principal Investigator: Victor Borin Centurion Biruel
• Grantee: Victor Borin Centurion Biruel
• Company: Microbiomex Biotecnologia e Soluções Microbianas Ltda
• CNAE: Atividades de serviços de complementação diagnóstica e terapêutica ; Atividades de atenção à saúde humana não especificadas anteriormente
• City: Campinas
• Associated scholarship(s): 24/03223-5 - BRIT: platform for detecting dysbiosis of the intestinal microbiome through genetic sequencing, BP.PIPE

Abstract

The intestinal microbiota (IM) comprises the population of bacteria and other microorganisms that inhabit the human intestine and play important roles in digestion, nutrient absorption, and protection against colonization by harmful bacteria. Recent studies also indicate an interaction of the intestinal microbiota with other organs such as the brain, skin, and immune system. Dysbiosis is the imbalance of this bacterial composition and may be related to various health problems such as obesity, inflammatory diseases, autoimmune diseases, and type 2 diabetes. Additionally, it interferes with the body's ability to absorb nutrients and defend itself against pathogens. Bacterial families that can cause dysbiosis include Enterobacteriaceae, Clostridiaceae, and Bacteroidaceae. Some beneficial bacteria that can help prevent or treat dysbiosis include Lactobacillaceae, Bifidobacteriaceae, and others that normally inhabit the intestine. For this reason, the study of the IM is of fundamental importance for human health and for understanding which other factors exert influence. The technological innovation platform aims to develop a continuously updated database for the detection of IM dysbiosis using 16S rRNA region sequencing, with the distinctive feature of employing machine learning techniques. This approach will allow for more accurate results compared to current analysis techniques, which only describe the abundance of bacteria found in libraries. Through the correlation of this data, it will be possible to create a dietary plan with the purpose of improving the quality of life for clients with physiological problems that may be related to IM disorders. Currently, there is no clinical tool for diagnosing intestinal dysbiosis, and it is typically done by doctors based on symptoms and conventional laboratory tests. To facilitate access to the test, a collection kit will be developed, allowing patients to collect a sample on their own. The company will also operate with a "pick-up and drop-off" system, enabling sample collection at a location and time previously scheduled by the client. Furthermore, a user-friendly platform will be created for doctors, nutritionists, and clients to access the obtained results. (AU)